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Evidence-based healthcare 10 
years on: is the National Institute 
of Clinical Studies the answer?
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TO THE EDITOR: The recent creation of
the National Institute for Clinical Studies
(NICS) is an exciting new opportunity for
bridging the gap between evidence and
practice.1
In carrying out this task, NICS will be
directed by the members of its Board.
Balanced stakeholder representation on the
Board is required for NICS to produce
optimal results. At present the Board
consists of nine members, of whom eight
are medical practitioners. The importance
of doctors in the process and
implementation of quality improvement
initiatives is indisputable. However, other
healthcare professionals also play a central
role in achieving quality health outcomes
for patients.2 Board membership more
representative of its stakeholders would
provide NICS with a broader range of
perspectives, which could only be seen as
beneficial.
Given the current debate surrounding
ethics and evidence-based healthcare, the
values and expectations of healthcare
consumers also need to be taken into
account.3 One of the definitions of quality
in healthcare is “consistently meeting or
exceeding informed customers’ opinion”.4
It is crucial that the consumer’s voice be
heard in matters relating to healthcare
research and in the implementation of
quality initiatives. As the relevance and
acceptability of quality initiatives under-
taken by NICS will have an impact on
health outcomes for consumers, it is
important that such initiatives take into
account the preferences of consumers. For
this reason, we believe it is imperative that
NICS include a consumer on its Board.
An example of successful integration of a
wide range of stakeholders onto a board is
the Federal Government-funded National
Health Priority Action Council, with
representation from State/Territory, Indige-
nous and consumer groups and a balanced
gender mix. We hope that NICS has
strategies in place to enhance stakeholder
representation on its Board, as this may be
a factor in determining whether or not
NICS becomes another forgettable
acronym.
1. Silagy C. Evidence-based healthcare 10 years on: is the
National Institute of Clinical Studies the answer [editorial]?
Med J Aust 2001; 175: 124-125.
2. Donabedian A. The quality of care: how can it be assessed?
JAMA 1988; 260: 1743-1748.
3. Leeder S, Rychetnik L. Ethics and evidence-based medi-
cine. Med J Aust 2001; 175: 161-164.
4. Headrick L, Neuhauser D. Quality health care. JAMA 1995;
273: 1718-1720. o
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IN REPLY: The Board of the National
Institute of Clinical Studies (NICS) agrees
strongly with Hall and Lauder that closing
the gap between evidence and practice
involves input from consumers. We also
agree that the Board of Directors should
seek to incorporate input from consumers
in its strategic and operational activities.
Of equal concern to the Board is ensuring
the input of other stakeholder groups also
currently not reflected in the composition of
Board membership. For example, nursing
and allied health professions comprise
about 80% of the healthcare workforce and
have shown strong leadership in relation to
evidence-based practice. We are keen to see
such groups actively involved in all aspects
of the Institute’s work.
As a Federal Government-owned
company, the selection and appointment
process for Board members is the
responsibility of government and our
constitution does not allow the Board to
change its own membership. However, the
Board is seeking input from both
consumers and other key stakeholder
groups, both through its initial consultation
processes and through establishment of
Board advisory groups specifically focused
on consumer issues and nursing and allied
health. These groups will provide direct and
valued input into the strategic and
operational activities of the NICS.
Our first round of consultation, with over
300 organisations, highlighted a number of
areas where there are currently major gaps
between evidence and practice, such as
cardiac failure, various forms of cancer
treatment, prevention of deep vein
thrombosis in hospitalised patients,
prevention of bedsores, and prescribing of
psychotropic drugs for children. We are
now examining ways in which the NICS
might usefully help in some of these areas to
identify barriers and possible solutions that
can be rolled out across the healthcare
system and sustained. The success of the
NICS in achieving this will depend on the
willingness of all stakeholders (including
health professionals, consumers and
managers) to work together in a
constructive way. o
COX-2 inhibition and 
thrombotic tendency
Christopher G Fenn
Area Medical Director, Australia/SE Asia, Pharmacia
Australia Pty Ltd, 59 Kirby Street, Rydalmere, NSW
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TO THE EDITOR: I am concerned that
several statements in the article on
cyclooxygenase-2 (COX-2) inhibition by
Cleland and colleagues1 do not accurately
reflect the clinical data.
The authors postulate a prothrombotic
tendency of celecoxib on the basis of the
CLASS study (comparing celecoxib with
ibuprofen or diclofenac)2 and four case
reports. The authors concede that celecoxib
has no effect on the rate of myocardial
infarction (MI) in the CLASS study (a
conclusion also reached by the United
States Food and Drug Administration
[FDA] review of CLASS3), which would
seem to contradict their hypothesis that
celecoxib is prothrombotic.
Cleland and colleagues speculate that the
differences between the CLASS study and
the VIGOR study (which compared
rofecoxib with naproxen)4 may be
explained by low-dose aspirin use in
CLASS and failure to use aspirin in 4% of
patients in VIGOR with “CV [cardiovacu-
lar] risk factors”. This speculation is
unfounded. In the CLASS study patients in
all treatment groups who used aspirin had
higher MI rates than non-aspirin users, and
presumably this higher rate would have
been observed in VIGOR if aspirin users
had been enrolled. This higher rate is
probably because aspirin use serves as a
marker for increased CV risk. In patients in
CLASS similar to the 4% with “CV risk
factors” in VIGOR, MI rates were similar in
the celecoxib and non-steroidal anti-
inflammatory drug (NSAID) groups (data
on file, Pharmacia) and numerically much
lower than in the VIGOR study subgroup.
On the basis of these two flawed
arguments, Cleland and colleagues
apparently extrapolate the high rate of MI
seen with the use of rofecoxib to celecoxib
and suggest that high MI rates are a “class”
effect. This proposal is scientifically
unsound and is not supported by other
clinical data, including over 12 000 patients
in the celecoxib registration program (data
on file, Pharmacia). No celecoxib study has
shown an increased risk of MI compared
with traditional NSAIDs.
The authors correctly assert there is
“little clinical evidence from community
use to suggest that selective COX-2
inhibition has serious unwanted effects
other than those seen with standard
NSAIDs”, but imply there are few
community data. In fact, community use of
celecoxib in Australia (at least 1.5 million
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patients exposed) and worldwide (more
than 20 million) has been extensive, and
with this degree of exposure one would
expect significant adverse event patterns to
emerge. Reference to the Adverse Drug
Reactions Advisory Committee and FDA
database does not indicate a prothrombotic
tendency of celecoxib. Further, we at
Pharmacia do not consider that the four
case studies presented by Cleland et al
provide strong support for a prothrombotic
tendency for celecoxib, especially as all
patients described had diseases with high
risk for thrombosis.
On the basis of a large body of controlled
trial data (including CLASS) and extensive
community exposure, the evidence does not
show any more thrombosis with celecoxib
than with NSAIDs.
Results of the CLASS and VIGOR
studies clearly differ. It is clinically
unjustified and scientifically unsound to
suggest that rates of MI seen with rofecoxib
can be ascribed to celecoxib and described
as a “class effect”.
1. Cleland LG, James MJ, Stamp LK, Penglis PS. COX-2
inhibition and thrombotic tendency: a need for surveillance.
Med J Aust 2001; 175: 214-217.
2. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal
toxicity with celecoxib vs nonsteroidal anti-inflammatory
drugs for osteoarthritis and rheumatoid arthritis: the CLASS
study: A randomized controlled trial. Celecoxib Long-term
Arthritis Safety Study. JAMA 2000; 284: 1247-1255.
3. Throckmorton DC. FDA Center for Drug Evaluation and
Research memorandum. Comparative safety of celecoxib,
diclofenac and ibuprofen. Rockville, MD: FDA, 1 May 2001.
<http://www.fda.gov/ohrms/dockets/ac/01/briefing/
3677b1_07.pdf>
4. Bombardier C, Laine L, Reicin A, et al. Comparison of upper
gastrointestinal toxicity of rofecoxib and naproxen in
patients with rheumatoid arthritis. N Engl J Med 2000; 343:
1520-1528. o
Leslie G Cleland,* Michael J James† 
*Director, † Chief Medical Scientist, Rheumatology 
Unit, Royal Adelaide Hospital, North Terrace, 
Adelaide, SA 5000. 
Lcleland@mail.rah.sa.gov.au
IN REPLY: The response from the Medical
Director of Pharmacia to our article
highlights some problems for all clinicians
and independent scientists seeking to
evaluate the balance of risks and benefits of
pharmaceuticals and to validate the
marketing messages of pharmaceutical
companies. On the one hand, we lack the
time and statistical resources to trawl
through all data related to all trials with a test
drug. On the other, our efforts to evaluate
data are confounded by the publication and
reporting biases associated with company-
sponsored studies. In this regard, it is
notable that the definitive results of CLASS1
have not been published, although the Food
and Drug Administration (FDA) review of
the data is available through an FDA
website,2 as indicated by Fenn. While this
document places data in the public domain,
its location is neither within the pathway of
MEDLINE search engines, nor is it known
to the general body of clinicians.
As reported in the FDA presentation,
CLASS was a very large, double-blind
safety study of at least six months’
treatment that failed to achieve its primary
endpoint of reduced complicated upper
gastrointestinal events with celecoxib
relative to the comparator, non-steroidal
anti-inflammatory drugs (NSAIDs). While
an interim analysis at six months was
published, with extrapolation of event rates
to 12 months,3 failure to publish the final
results has withheld important results from
wider scrutiny. In essence, the FDA
document shows no overall long-term
safety advantage of celecoxib over standard
NSAIDs.2 
The FDA analysis4 of the VIGOR study5
also shows no overall safety advantage for
rofecoxib compared with NSAID, with
fewer complicated upper gastrointestinal
events being offset by a highly statistically
significant (P = 0.0016) increase in serious
thrombotic cardiovascular events. 
Collectively, these FDA analyses
invalidate the promotion of selective
cyclooxygenase-2 (COX-2) inhibitors as a
safe alternative to NSAIDs, notwithstand-
ing encouraging results from short-term
trials. Further, although an increase in
serious cardiovascular events was not seen
in the CLASS study, its design was not
optimal for detecting increased cardiovas-
cular risk, and it is unlikely that CLASS was
sufficiently powered to detect the degree of
increased risk seen with rofecoxib in
VIGOR. As explained in our article,6
unbalanced prothrombotic eicosanoid
production associated with selective COX-
2 inhibition (ie, a class effect) appears the
most likely explanation for the increased
cardiovascular events seen in VIGOR.
Finally, we wish to reassert that, for
effective postmarketing surveillance, it is
essential that prescribers be adequately
informed about safety concerns associated
with new drugs, particularly when they
involve events that are common and not
usually seen as unwanted drug effects.
1 Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal
toxicity with celecoxib vs nonsteroidal anti-inflammatory
drugs for osteoarthritis and rheumatoid arthritis: the CLASS
study: A randomized controlled trial. Celecoxib Long-term
Arthritis Safety Study. JAMA 2000; 284: 1247-1255.
2. US Food and Drug Authority. NDA 20-998/S-009. Celebrex
capsules (Celecoxib). Medical Officer Review. Sept 2001
<http://www.fda.gov/ohrms/dockets/ac/01/briefing/
3677b1_03_med.doc>
3. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal
toxicity with celecoxib vs nonsteroidal anti-inflammatory
drugs for osteoarthritis and rheumatoid arthritis: the CLASS
study: A randomized controlled trial. Celecoxib Long-term
Arthritis Safety Study. JAMA 2000; 284: 1247-1255.
4. FDA Advisory Committee Briefing Document, NDA 21-042,
s007, VIOXX Gastrointestinal Safety <http://www.fda.gov/
ohrms/dockets/ac/01/briefing/3677b2_03_med.pdf>
5. Bombardier C, Laine L, Reicin A, et al. Comparison of upper
gastrointestinal toxicity of rofecoxib and naproxen in
patients eith rheumatoid arthritis. N Engl J Med 2000; 343:
1520-1528.
6. Cleland LG, James MJ, Stamp LK, Penglis PS. COX-2
inhibition and thrombotic tendency: a need for surveillance.
Med J Aust 2001; 175: 214-217. o
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TO THE EDITOR: Chronic hepatitis C
(HCV) infection affects more than 200 000
Australians.1 As the degree of hepatic
fibrosis is the best predictor of morbidity,
liver biopsy has a central role in
management. Biopsy is also carried out to
exclude additional pathology. However,
because liver biopsy carries real risks and is
expensive,2,3 debate exists as to whether
liver biopsy should be performed
routinely.3,4 Despite controversy surround-
ing the need to treat patients with minor
histological changes,4 our impression is that
many informed patients request treatment
irrespective of liver histology. In Australia,
liver biopsy is a prerequisite for antiviral
therapy under the Pharmaceutical Benefits
Scheme Highly Specialised Drugs Program
(Box).5 
To assess the impact of liver biopsy on
management, we performed a retrospective
study of patients with chronic HCV
infection who underwent liver biopsy from
March 1998 to December 2000. We
identified 76 patients (51 men, 25 women),
with a mean age of 29 years (range, 20–52
years). The biopsy was performed to stage
and grade hepatitis C in all patients, and
additionally to investigate a second
pathology in seven patients. No alternative
diagnoses were raised. Additional diagnoses
(all suspected before biopsy) were
confirmed in three patients and refuted in
four patients. Biopsy findings were all
consistent with chronic HCV infection,
with some degree of fibrosis in 69 patients.
There were five patients with histologically
confirmed cirrhosis (including incomplete
cirrhosis in three), and this was clinically
evident in two patients. When S100 criteria
at the time of biopsy were applied, after
exclusions on clinical grounds, only one
patient would have been ineligible for
interferon monotherapy based on liver
histology. Under current S100 criteria, nine
patients would be ineligible for combination
therapy, but all nine would remain eligible
for monotherapy. Of our patients who
attended follow-up and were HCV RNA
positive, 62 of 64 patients received or are
awaiting therapy.
Our results confirm the finding that liver
biopsy in patients with chronic HCV
infection rarely identifies alternative
diagnoses.3 These data reflect the fact that
